Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
Vencken PMLH, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C. Vencken PMLH, et al. Among authors: kriege m. Ann Oncol. 2011 Jun;22(6):1346-1352. doi: 10.1093/annonc/mdq628. Epub 2011 Jan 12. Ann Oncol. 2011. PMID: 21228333 Free article.
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG. Rijnsburger AJ, et al. Among authors: kriege m. J Clin Oncol. 2010 Dec 20;28(36):5265-73. doi: 10.1200/JCO.2009.27.2294. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079137 Clinical Trial.
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Zaaijer LH, van Doorn HC, Mourits MJ, van Beurden M, de Hullu JA, Adank MA, van Lonkhuijzen LR, Vasen HF, Slangen BF, Gaarenstroom KN, Zweemer RP, Vencken PM, Seynaeve C, Kriege M. Zaaijer LH, et al. Among authors: kriege m. Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18. Br J Cancer. 2016. PMID: 27755534 Free PMC article.
Survival and prognostic factors in BRCA1-associated breast cancer.
Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG. Brekelmans CT, et al. Among authors: kriege m. Ann Oncol. 2006 Mar;17(3):391-400. doi: 10.1093/annonc/mdj095. Epub 2005 Dec 1. Ann Oncol. 2006. PMID: 16322115 Free article.
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG. Brekelmans CT, et al. Among authors: kriege m. Eur J Cancer. 2007 Mar;43(5):867-76. doi: 10.1016/j.ejca.2006.12.009. Epub 2007 Feb 20. Eur J Cancer. 2007. PMID: 17307353
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C. Vencken PM, et al. Among authors: kriege m. Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29. Ann Oncol. 2013. PMID: 23543211 Free article.
91 results